Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$644.37M-$644.37MN/M vs Q2 2025 EPS Diluted-$3.06-$3.06N/M vs Q2 2025 Operating Income-$505,132,000N/M Operating Cash Flowderived-$387,319,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Free Cash Flowderived-$389,605,000N/M ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end